LONDON, March 11, 2020 /PRNewswire/ -- Nasdaq and AIM listed Tiziana Life Sciences plc TLSA TILS has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure.
Tiziana, a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, is expediting development of TZLS-501, with Novimmune, SA, a Swiss biotechnology company with whom it entered into a world-wide license for composition-of-matter in 2017.
Tiziana plans to administer TZLS-501 using a proprietary formulation technology. Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood. An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness.
Dr. Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences said; "We are excited to move forward with our clinical development plan to expedite evaluation in patients as soon as possible."
For further enquiries:
Tiziana Life Sciences plc
Tiziano lazzaretti
+44 (0) 207-495-2379
Novus Communications
Alan Green/ John Brennan
+44 0207-448-9839
View original content:http://www.prnewswire.com/news-releases/tiziana-life-sciences-developing-tzls-501-as-a-potential-treatment-for-coronavirus-patients-301021437.html
SOURCE Tiziana Life Sciences plc
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.